Cargando…

Association of Other Autoimmune Diseases With Thyroid Eye Disease

BACKGROUND: Thyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been shown to affect AI disease severity, its influenc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelada, Mary, Avari, Parizad, Farag, Soma, Akishar, Rashmi, Jain, Rajni, Aziz, Ahmad, Feeney, Claire, Bravis, Vassiliki, Meeran, Karim, Lee, Vickie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973359/
https://www.ncbi.nlm.nih.gov/pubmed/33746907
http://dx.doi.org/10.3389/fendo.2021.644200
_version_ 1783666827937710080
author Kelada, Mary
Avari, Parizad
Farag, Soma
Akishar, Rashmi
Jain, Rajni
Aziz, Ahmad
Feeney, Claire
Bravis, Vassiliki
Meeran, Karim
Lee, Vickie
author_facet Kelada, Mary
Avari, Parizad
Farag, Soma
Akishar, Rashmi
Jain, Rajni
Aziz, Ahmad
Feeney, Claire
Bravis, Vassiliki
Meeran, Karim
Lee, Vickie
author_sort Kelada, Mary
collection PubMed
description BACKGROUND: Thyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been shown to affect AI disease severity, its influence on TED severity has never been investigated. The prevalence of polyautoimmunity among TED patients is also unclear, with discordant results reported in the literature. This study evaluates the prevalence of non-thyroid/“other” AI (OAI) conditions in an ethnically diverse TED cohort and assesses how polyautoimmunity affects TED severity and activity. METHODS: A retrospective study of patients presenting to multidisciplinary TED clinics across three North-West London hospitals between 2011 and 2019. Data collected included: 1) demographics; 2) OAI conditions and management; 3) endocrine management of thyroid dysfunction; 4) details of TED and clinical activity score at presentation. RESULTS: Two hundred and sixty-seven patients with a median age of 46 (35–54) years were included, 79.4% were female and 55% were Black, Asian and minority ethnic (BAME). Thirty-seven patients (13.9%) had OAI conditions, with rheumatoid arthritis (3.7%), vitiligo (3.0%) and psoriasis (3.0%) among the most prevalent. Of patients with OAI conditions, 43.2% (16/37) required immunosuppression prior to TED onset. Non-immunosuppressed patients with OAI conditions had a significantly higher clinical activity score at presentation than TED-only and previously immunosuppressed patients (p=0.02). No significant differences were observed in thyroid receptor antibody titers between these groups. CONCLUSIONS: This study finds a 13.9% prevalence of OAI conditions among TED patients. Patients with OAI conditions overall have a tendency for more severe and significantly more clinically active TED than those without OAI conditions. Larger, prospective studies are warranted to further evaluate polyautoimmunity as an early predictor of TED severity.
format Online
Article
Text
id pubmed-7973359
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79733592021-03-20 Association of Other Autoimmune Diseases With Thyroid Eye Disease Kelada, Mary Avari, Parizad Farag, Soma Akishar, Rashmi Jain, Rajni Aziz, Ahmad Feeney, Claire Bravis, Vassiliki Meeran, Karim Lee, Vickie Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Thyroid eye disease (TED) is a potentially disfiguring and sight-threatening autoimmune (AI) orbitopathy, affecting up to 400,000 people in the UK. There are no accurate early predictors of TED severity. Although polyautoimmunity has been shown to affect AI disease severity, its influence on TED severity has never been investigated. The prevalence of polyautoimmunity among TED patients is also unclear, with discordant results reported in the literature. This study evaluates the prevalence of non-thyroid/“other” AI (OAI) conditions in an ethnically diverse TED cohort and assesses how polyautoimmunity affects TED severity and activity. METHODS: A retrospective study of patients presenting to multidisciplinary TED clinics across three North-West London hospitals between 2011 and 2019. Data collected included: 1) demographics; 2) OAI conditions and management; 3) endocrine management of thyroid dysfunction; 4) details of TED and clinical activity score at presentation. RESULTS: Two hundred and sixty-seven patients with a median age of 46 (35–54) years were included, 79.4% were female and 55% were Black, Asian and minority ethnic (BAME). Thirty-seven patients (13.9%) had OAI conditions, with rheumatoid arthritis (3.7%), vitiligo (3.0%) and psoriasis (3.0%) among the most prevalent. Of patients with OAI conditions, 43.2% (16/37) required immunosuppression prior to TED onset. Non-immunosuppressed patients with OAI conditions had a significantly higher clinical activity score at presentation than TED-only and previously immunosuppressed patients (p=0.02). No significant differences were observed in thyroid receptor antibody titers between these groups. CONCLUSIONS: This study finds a 13.9% prevalence of OAI conditions among TED patients. Patients with OAI conditions overall have a tendency for more severe and significantly more clinically active TED than those without OAI conditions. Larger, prospective studies are warranted to further evaluate polyautoimmunity as an early predictor of TED severity. Frontiers Media S.A. 2021-03-05 /pmc/articles/PMC7973359/ /pubmed/33746907 http://dx.doi.org/10.3389/fendo.2021.644200 Text en Copyright © 2021 Kelada, Avari, Farag, Akishar, Jain, Aziz, Feeney, Bravis, Meeran and Lee http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Kelada, Mary
Avari, Parizad
Farag, Soma
Akishar, Rashmi
Jain, Rajni
Aziz, Ahmad
Feeney, Claire
Bravis, Vassiliki
Meeran, Karim
Lee, Vickie
Association of Other Autoimmune Diseases With Thyroid Eye Disease
title Association of Other Autoimmune Diseases With Thyroid Eye Disease
title_full Association of Other Autoimmune Diseases With Thyroid Eye Disease
title_fullStr Association of Other Autoimmune Diseases With Thyroid Eye Disease
title_full_unstemmed Association of Other Autoimmune Diseases With Thyroid Eye Disease
title_short Association of Other Autoimmune Diseases With Thyroid Eye Disease
title_sort association of other autoimmune diseases with thyroid eye disease
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973359/
https://www.ncbi.nlm.nih.gov/pubmed/33746907
http://dx.doi.org/10.3389/fendo.2021.644200
work_keys_str_mv AT keladamary associationofotherautoimmunediseaseswiththyroideyedisease
AT avariparizad associationofotherautoimmunediseaseswiththyroideyedisease
AT faragsoma associationofotherautoimmunediseaseswiththyroideyedisease
AT akisharrashmi associationofotherautoimmunediseaseswiththyroideyedisease
AT jainrajni associationofotherautoimmunediseaseswiththyroideyedisease
AT azizahmad associationofotherautoimmunediseaseswiththyroideyedisease
AT feeneyclaire associationofotherautoimmunediseaseswiththyroideyedisease
AT bravisvassiliki associationofotherautoimmunediseaseswiththyroideyedisease
AT meerankarim associationofotherautoimmunediseaseswiththyroideyedisease
AT leevickie associationofotherautoimmunediseaseswiththyroideyedisease